PSC
SEEL

Piper Sandler & Co’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Piper Sandler & Co’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-43
Closed -$361K – 27
2019
Q2 		$361K Buy
+43
New +$453K 0.48% 10

Other funds holding SEEL

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Piper Sandler & Co's SEEL Position: Q3 2019 in Review

Piper Sandler & Co sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q3 2019, closing a stake of 43 shares — an estimated $361K sold.

Piper Sandler & Co first reported a position in SEEL in Q2 2019 and held it in 1 quarter. The position peaked at $361K in Q2 2019. 20 funds tracked by Wall St. Rank hold SEEL as of Q3 2019.

  • Piper Sandler & Co reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
  • Piper Sandler & Co sold 43 Seelos Therapeutics, Inc. Common Stock shares in Q3 2019, an estimated $361K.
  • Piper Sandler & Co first reported a position in Seelos Therapeutics, Inc. Common Stock in Q2 2019 and held it in 1 quarter.
  • Piper Sandler & Co's Seelos Therapeutics, Inc. Common Stock position peaked at $361K in Q2 2019.
  • 20 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q3 2019.

Based on Piper Sandler & Co's 13F filing for Q3 2019, filed 14 Nov 2019.